CA2768772A1 - Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients - Google Patents

Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients Download PDF

Info

Publication number
CA2768772A1
CA2768772A1 CA2768772A CA2768772A CA2768772A1 CA 2768772 A1 CA2768772 A1 CA 2768772A1 CA 2768772 A CA2768772 A CA 2768772A CA 2768772 A CA2768772 A CA 2768772A CA 2768772 A1 CA2768772 A1 CA 2768772A1
Authority
CA
Canada
Prior art keywords
hepatitis
treatment
subject
nucleic acid
polymorphic marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2768772A
Other languages
English (en)
French (fr)
Inventor
Pierre-Yves Bochud
Andri Rauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bern
University Hospital of Lausanne
Original Assignee
University of Bern
University Hospital of Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bern, University Hospital of Lausanne filed Critical University of Bern
Publication of CA2768772A1 publication Critical patent/CA2768772A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2768772A 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients Abandoned CA2768772A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH01201/09 2009-07-31
CH12012009 2009-07-31
US28253810P 2010-02-26 2010-02-26
US61/282,538 2010-02-26
PCT/IB2010/053139 WO2011013019A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients

Publications (1)

Publication Number Publication Date
CA2768772A1 true CA2768772A1 (en) 2011-02-03

Family

ID=42727569

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768772A Abandoned CA2768772A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients

Country Status (10)

Country Link
US (1) US20110165124A1 (enExample)
EP (1) EP2459210A1 (enExample)
JP (1) JP2013500713A (enExample)
KR (1) KR20120040725A (enExample)
CN (1) CN102665753A (enExample)
AU (1) AU2010277239A1 (enExample)
BR (1) BR112012001931A2 (enExample)
CA (1) CA2768772A1 (enExample)
MX (1) MX2012001058A (enExample)
WO (1) WO2011013019A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656159B2 (ja) * 2009-08-24 2015-01-21 独立行政法人理化学研究所 インターフェロン療法の効果予測用マーカー
BR112012018342A2 (pt) * 2009-12-22 2017-01-10 Janssen R&D Ireland "valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente."
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
KR20140007927A (ko) * 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
EP2726632A1 (en) * 2011-06-30 2014-05-07 Centre Hospitaller Universitaire Vaudois (CHUV) Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
BR112014002365A2 (pt) 2011-08-03 2017-02-21 Cytheris interleucina-7 (il-7)
JP2013074888A (ja) * 2011-09-15 2013-04-25 Arkray Inc ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法
WO2013052862A1 (en) * 2011-10-05 2013-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetic marker for predicting prognosis in patients infected with hepatitis c virus
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US9678074B2 (en) 2012-03-28 2017-06-13 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001050A (en) 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1997001603A1 (en) 1995-06-26 1997-01-16 Henkel Corporation Methods of preparing inorganic pigment dispersions
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US7060431B2 (en) 1998-06-24 2006-06-13 Illumina, Inc. Method of making and decoding of array sensors with microspheres
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc Ｃ型肝炎ウイルス感染者の経過に関する遺伝子およびその利用
EP1778861A4 (en) * 2004-07-01 2008-11-19 Medical Res Fund At The Tel Av METHODS AND KITS FOR PREDICTING THE SPEED OF PROGRESSION OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
WO2010025380A2 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
AU2010249379B2 (en) * 2009-05-21 2013-09-26 Merck Sharp & Dohme Corp. Genetic markers associated with interferon-alpha response

Also Published As

Publication number Publication date
KR20120040725A (ko) 2012-04-27
WO2011013019A1 (en) 2011-02-03
US20110165124A1 (en) 2011-07-07
MX2012001058A (es) 2012-06-19
CN102665753A (zh) 2012-09-12
BR112012001931A2 (pt) 2017-07-18
AU2010277239A1 (en) 2012-02-02
EP2459210A1 (en) 2012-06-06
JP2013500713A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
US20110165124A1 (en) Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
Abe et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy
US20120183497A1 (en) Method of Determining Response to Treatment with Immunomodulatory Composition
Serajee et al. Polymorphisms in xenobiotic metabolism genes and autism
US20070037183A1 (en) Diagnostic and therapeutic target for macular degeneration
RU2606759C2 (ru) Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с
JP2023552199A (ja) コロナウイルス感染症を発症するリスクが高い対象を特定する方法及びその治療法
WO2011146985A1 (en) Method of determining response to treatment with immunomodulatory composition
JP2013529068A (ja) Ｈｃｖ治療における早期ウイルス応答の予測
US20140154209A1 (en) Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
US20140271542A1 (en) Genetic marker for predicting prognosis in patients infected with hepatitis c virus
Lange et al. HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection
EP2516674A1 (en) Mutant ldl receptor gene
WO2013030786A1 (en) Method for diagnosing or predicting hepatocellular carcinoma outcome
Class et al. Patent application title: POLYMORPHISMS ASSOCIATED WITH NON-RESPONSE TO A HEPATITIS C TREATMENT OR SUSCEPTIBILITY TO NON-SPONTANEOUS HEPATITIS C CLEARANCE Inventors: Stephanie Bibert (Divonne-Les-Bains, FR) Pierre-Yves Bochud (Grandvaux, CH) Assignees: Centre Hospitalier Universitaire Vaudois
HK1176284A (en) Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
CN114540479A (zh) 用于检测与耳聋相关的基因snp的组合物、试剂盒及检测方法
US20130203054A1 (en) Antiviral treatment susceptibility gene and uses thereof
KR20160148807A (ko) 장 베체트병 진단용 바이오마커 및 이의 용도
JP5695181B2 (ja) Ｈｃｖ治療成果を予測する一塩基多型
US20100284966A1 (en) Methods and Compositions for Managing Resistance of Hepatitis C Virus to Immunosuppressant
KR100658606B1 (ko) Ｃ형 간염 바이러스의 유전자형 분석방법
WO2012145794A1 (en) Method of determining response to treatment with immunomodulatory composition
Ito et al. Associated with Interleukin-28B

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150709